Mesoblast Ltd
MESO10.160USD
-0.275-2.64%
收盤 06/23, 16:00（美東）報價延遲15分鐘
1.17B總市值
虧損本益比TTM
關於 Mesoblast Ltd 公司
Mesoblast Limited 是一家總部位於澳大利亞的公司，致力於開發用於治療嚴重和危及生命的炎症疾病的同種異體（現成）細胞藥物。該公司利用其專有的間充質譜系細胞治療技術平臺建立了廣泛的後期候選產品組合。該公司正在基於其 remestemcel-L 和 rexlemestrocel-L 同種異體基質細胞技術平臺開發用於不同適應症的候選產品。Remestemcel-L 正在開發用於兒童和成人炎症疾病，包括類固醇難治性急性移植物抗宿主病和生物耐藥性炎症性腸病。Rexlemestrocel-L 正在開發用於治療晚期慢性心力衰竭 (REVASCOR) 和慢性腰痛 (MPC-06-ID)。該公司的許可方已在日本和歐洲商業化了兩種產品。該公司已在歐洲和中國建立了某些 III 期資產的商業夥伴關係。
公司簡介
公司代碼MESO
公司名稱Mesoblast Ltd
上市日期Dec 16, 2004
成立日期2004
CEODr. Silviu Itescu
員工數量73
證券類型Depository Receipt
年結日Dec 16
公司地址L 38 55 Collins St
城市MELBOURNE
上市交易所NASDAQ Global Select Consolidated
國家Australia
郵編3000
電話61396396036
網址https://www.mesoblast.com/
公司代碼MESO
上市日期Dec 16, 2004
成立日期2004
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Eric A. Rose, M.D.
Dr. Eric A. Rose, M.D.
Executive Director, Chief Medical Officer
Executive Director, Chief Medical Officer
41.16K
--
Dr. Fiona See, Ph.D.
Dr. Fiona See, Ph.D.
Senior Vice President, Head - Translational Research
Senior Vice President, Head - Translational Research
--
--
Mr. William M. (Bill) Burns
Mr. William M. (Bill) Burns
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Mr. Philip R. Krause, M.D.
Mr. Philip R. Krause, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Paul Hughes
Mr. Paul Hughes
Joint Company Secretary
Joint Company Secretary
--
--
Dr. Fiona See, Ph.D.
Dr. Fiona See, Ph.D.
Senior Vice President, Head - Translational Research
Senior Vice President, Head - Translational Research
--
--
Mr. Philip J. (Phil) Facchina
Mr. Philip J. (Phil) Facchina
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Niva Sivakumar
Ms. Niva Sivakumar
Joint Company Secretary
Joint Company Secretary
--
--
Mr. Paul Hughes
Mr. Paul Hughes
Joint Company Secretary
Joint Company Secretary
--
--
Ms. Niva Sivakumar
Ms. Niva Sivakumar
Joint Company Secretary
Joint Company Secretary
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Eric A. Rose, M.D.
Dr. Eric A. Rose, M.D.
Executive Director, Chief Medical Officer
Executive Director, Chief Medical Officer
41.16K
--
Dr. Fiona See, Ph.D.
Dr. Fiona See, Ph.D.
Senior Vice President, Head - Translational Research
Senior Vice President, Head - Translational Research
--
--
Mr. William M. (Bill) Burns
Mr. William M. (Bill) Burns
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Mr. Philip R. Krause, M.D.
Mr. Philip R. Krause, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Paul Hughes
Mr. Paul Hughes
Joint Company Secretary
Joint Company Secretary
--
--
Dr. Fiona See, Ph.D.
Dr. Fiona See, Ph.D.
Senior Vice President, Head - Translational Research
Senior Vice President, Head - Translational Research
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月17日 週六
更新時間: 5月17日 週六
持股股東
股東類型
持股股東
持股股東
佔比
BlackRock Institutional Trust Company, N.A.
0.44%
Citadel Advisors LLC
0.38%
Morgan Stanley & Co. International Plc
0.25%
Susquehanna International Group, LLP
0.20%
Goldman Sachs & Company, Inc.
0.20%
Other
98.52%
持股股東
持股股東
佔比
BlackRock Institutional Trust Company, N.A.
0.44%
Citadel Advisors LLC
0.38%
Morgan Stanley & Co. International Plc
0.25%
Susquehanna International Group, LLP
0.20%
Goldman Sachs & Company, Inc.
0.20%
Other
98.52%
股東類型
持股股東
佔比
Investment Advisor
1.46%
Research Firm
0.99%
Hedge Fund
0.45%
Investment Advisor/Hedge Fund
0.20%
Individual Investor
0.06%
Other
96.83%
機構持股
更新時間: 3月4日 週二
更新時間: 3月4日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q1
121
3.21M
2.52%
-64.68K
2024Q4
122
3.23M
2.55%
+620.09K
2024Q3
100
1.76M
1.52%
-1.23M
2024Q2
98
1.70M
1.52%
-705.91K
2024Q1
97
1.24M
1.12%
-806.95K
2023Q4
94
840.17K
0.85%
-1.02M
2023Q3
97
766.21K
0.94%
-1.35M
2023Q2
99
982.29K
1.21%
-1.15M
2023Q1
103
1.33M
1.81%
-837.80K
2022Q4
108
1.43M
1.94%
-964.96K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
BlackRock Institutional Trust Company, N.A.
584.29K
0.46%
+584.29K
--
Dec 31, 2024
Morgan Stanley & Co. International Plc
163.50K
0.13%
+163.50K
--
Dec 31, 2024
Susquehanna International Group, LLP
153.98K
0.12%
+37.24K
+31.90%
Dec 31, 2024
Morgan Stanley & Co. LLC
225.25K
0.18%
+54.27K
+31.74%
Dec 31, 2024
Summit Wealth Strategies
145.66K
0.11%
-2.04K
-1.38%
Dec 31, 2024
UBS Financial Services, Inc.
165.15K
0.13%
+165.15K
--
Dec 31, 2024
查看更多
持股ETF
更新時間: 6月6日 週五
更新時間: 6月6日 週五
機構名稱
佔比
iShares Biotechnology ETF
0.09%
Invesco Nasdaq Biotechnology ETF
0.04%
ProShares Ultra Nasdaq Biotechnology
0.04%
ActivePassive International Equity ETF
0.01%
iShares Biotechnology ETF
佔比0.09%
Invesco Nasdaq Biotechnology ETF
佔比0.04%
ProShares Ultra Nasdaq Biotechnology
佔比0.04%
ActivePassive International Equity ETF
佔比0.01%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Dec 22, 2023
Merger
2<1
Dec 22, 2023
Merger
2<1
Dec 22, 2023
Merger
2<1
Dec 22, 2023
Merger
2<1
公告日期
類型
比率
Dec 22, 2023
Merger
2<1
Dec 22, 2023
Merger
2<1
Dec 22, 2023
Merger
2<1
Dec 22, 2023
Merger
2<1
